secwatch.observer — SEC 8-K summary
======================================

Issuer:     Stoke Therapeutics, Inc. (STOK)
CIK:        0001623526
Form:       8-K
Filed at:   2026-09-25T20:05:49+00:00
Accession:  0001193125-26-402820
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02
LLM model:  deepseek-v4.1-flash:cloud@v2

Stoke Therapeutics director Edward Kaye resigns; board appoints Alexander Cumbo to Class III seat
--------------------------------------------------------------------------------

- Edward M. Kaye, M.D. resigned as a Class III director and Research and Development Committee member effective Sept. 23, 2026; resignation was not due to any disagreement with Stoke Therapeutics.
- The board appointed Alexander (Bo) Cumbo as a Class III director effective Sept. 23, 2026, to fill Kaye's vacancy; his term expires at the 2028 annual stockholders meeting.
- Cumbo is independent under SEC and Nasdaq rules and has no Item 404(a) related-party transactions with Stoke; he entered Stoke's standard director indemnity agreement.
- Under Stoke's non-employee director compensation program, Cumbo receives a $45,000 annual cash retainer and an initial option for 39,674 shares with a target grant date fair value of about $724,000.
- The option vests in twelve substantially equal quarterly installments on each quarterly anniversary of the grant date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1623526/000119312526402820/0001193125-26-402820-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1623526/000119312526402820/d136438d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-402820

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer